Instrument Inactif

Communiqués Icosavax, Inc.

Actions

ICVX

US45114M1099

Recherche biotechnologique et médicale

Communiqués

20/02/24	AstraZeneca - Acquisition of Icosavax Completed	AQ
01/02/24	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm	PR
29/12/23	ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX	BU
15/12/23	ICOSAVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX	BU
13/12/23	SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of Icosavax; Is the Deal in the Best Interest of Shareholders?	BU
12/12/23	Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca	AQ
12/12/23	Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults	AQ
14/11/23	Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update	AQ
08/11/23	Icosavax to Participate in the Jefferies London Healthcare Conference	AQ
31/10/23	Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference	AQ
17/10/23	Icosavax : October 2023 Corporate Presentation	PU
22/09/23	Icosavax : September 2023 Corporate Presentation	PU
19/09/23	Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023	AQ
29/08/23	Icosavax : Corporate Overview	PU
14/08/23	Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update	AQ
08/08/23	Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential	AQ
21/06/23	Icosavax : Corporate Overview	PU
20/06/23	Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults	AQ
05/06/23	Icosavax : Corporate Overview	PU
23/05/23	ICOSAVAX, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
22/05/23	Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock	AQ
22/05/23	Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults	AQ
22/05/23	Icosavax : IVX A12 Phase 1 Topline Data	PU
22/05/23	ICOSAVAX, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/05/23	Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update	AQ